The Mariposa study showed that a combination of two Johnson & Johnson (J&J) drugs, Rybrevant, and lazertinib, was successful in improving progression-free survival in a common type of metastatic lung tumor, compared to AstraZeneca's Tagrisso. These interim results have been closely […]
Latest Stories
Integration of Digital Targeting in Addressable TV: Implications for Healthcare Marketers
Addressable TV—which uses digital targeting and measurements for television advertisements—is changing the marketing landscape. It allows healthcare marketers to reach specific audiences with high precision, enhancing the effectiveness of advertising campaigns. During a panel discussion, industry […]
Philip Morris Introduces LEVIA: A Tobacco-Free Alternative for IQOS Device
Philip Morris International (PMI) has announced a new product for its IQOS 'heat-not-burn' device: a tobacco-free stick named LEVIA. The sticks use a 'non-tobacco substrate' infused with nicotine and come in various flavors. The tobacco company claims that LEVIA might not fall under the same tax […]
Unveiling the NHS Data Landscape: First Comprehensive Mapping for Improved Transparency and Efficiency
Researchers from the Institute of Global Health Innovation at Imperial College London have mapped and evaluated all electronic data flows in the NHS for the first time, revealing a complex landscape with tens of thousands of data transactions. This important research, published in The Lancet Digital […]
Roche Acquires Two RNA-Targeted Drug Programs for Alzheimer’s and Huntington’s from Ionis Pharmaceuticals
Roche has obtained two RNA-targeted drug programs for Alzheimer's and Huntington's diseases from Ionis Pharmaceuticals. The deal involves a $60 million upfront payment for the global exclusive rights, with further milestone payments and royalties possible. If approved, Roche will also handle […]
Galecto Laying Off 70% of Staff and Exploring Strategic Alternatives after Failed Lung Disease Drug Trial
Boston-based biotech firm Galecto plans to lay off 29 employees, approximately 70% of its workforce, after its lung disease drug candidate GB0139 failed in a phase IIb trial. Following the unsuccessful trial and predicted resource changes hinted at in mid-August, Galecto is now pursuing strategic […]
Class-Action Lawsuit Targets Johnson & Johnson and IBM after Data Breach
Johnson & Johnson and IBM face a proposed class-action lawsuit following a data breach at J&J’s Janssen CarePath patient assistance program. A Florida resident has claimed that the companies failed to adequately protect personal identity and health information according to industry standards […]
Higher Suicide Risk Among Health Care Workers, Especially Women: Study Reveals
A new study in the Journal of the American Medical Association suggests that health care workers, particularly registered nurses, health technicians and support workers, have a significantly higher risk of suicide than the general population. This is the first study to encompass all roles within the […]
UK’s Centre for Process Innovation Opens £26.4M RNA Centre of Excellence for Vaccine Production
The Centre for Process Innovation (CPI) in England has launched a £26.4 million ($32 million) plant named the RNA Centre of Excellence, which will facilitate the production of RNA products for early-stage clinical trials. The facility can potentially manufacture 100 million vaccines a year during […]
Christine Davis Appointed as New President of Ontada
Ontada, a McKesson business focusing on oncology real-world data and evidence, has appointed Christine Davis as its new President. She brings 25 years of experience in the life sciences industry, particularly in oncology research and real-world data. Davis aims to expand Ontada's business, promote […]
